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Introduction: Soluble mesothelin-related peptides (SMRP) have 
been reported as potential markers for the diagnosis of malignant 
pleural mesothelioma (MPM). We wondered, whether a combination 
with a carcinoembryonic antigen (CEA) test might improve the rela-
tively low diagnostic yield of the SMRP test.
Methods: In a retrospective study, SMRP (mesothelin) and CEA 
serum concentrations were measured, using commercially avail-
able kits, in 93 previously untreated MPM patients, 75 patients 
with benign asbestos disease, and 139 patients suffering from lung 
cancer (LC).
Results: The differentiation between MPM, LC, and benign 
asbestos disease could be improved by applying the ratio mesothe-
lin/CEA. Whereas CEA expression was found to be low in MPM, 
most LC patients had elevated CEA serum levels. The area under 
curve (AUC) of the receiver operator characteristics curve for 
mesothelin alone was found to be only 0.708. For mesothelin/CEA 
the AUC of the receiver operator characteristics curve increased 
to 0.978. The sensitivity was 93% (69%) at 95% (100%) speci-
ficity for the differentiation between MPM and LC. Comparison 
of MPM and benign asbestos disease showed that the AUC was 
0.887 and the sensitivity 56% (47%) at 95% (100%) specificity. 
In contrast, the AUC for the mesothelin test alone was only 0.715, 
and for the CEA test alone it was 0.16. An average increment in 
sensitivity of 38% (range, 16%–63%) could be achieved by the 
quotient mesothelin/CEA compared with the sensitivity of meso-
thelin alone.
Conclusion: The diagnostic yield of the mesothelin test can be con-
siderably improved when combined with a CEA test with regard to 
the differential diagnosis between MPM and LC and between MPM 
and benign asbestos disease.
Key Words: Soluble mesothelin-related proteins, Mesothelioma, 
Lung cancer, Asbestosis, Carcinoembryonic antigen.
(J Thorac Oncol. 2013;8: 947-951)
The number of occupational compensated asbestos-induced diseases in Germany is still rising. Currently, approxi-
mately three quarters (74.6%) of all occupational cancers 
eligible for compensation are ascribed to asbestos fibers.1 
Because of the latency period the incidence of malignant 
mesothelioma will continue to increase, with a peak expected 
between the years 2015 and 2020.
Effective treatment of asbestos-induced malignancies 
requires a confirmation of the diagnosis. Histopathological 
and cytological examinations are necessary for discrimi-
nation between either malignant pleural mesothelioma 
(MPM) and pleural metastasis from lung cancer (LC), 
or from benign asbestos disease, like rounded atelecta-
sis, which may mimic a tumor mass. Cytology is able to 
identify MPM only in a minority of cases (30%–50%).2 
Histological differentiation between adenocarcinoma (AC) 
of the lung and mesothelioma is often indistinguishable.2 In 
addition, the prognosis of these malignancies is essentially 
poor because of disease detection mostly at an advanced 
stage and the high resistance of MPM to radiotherapy and 
chemotherapy.
Tumor markers should help to establish the differential 
diagnosis between MPM, primary LC, and benign asbestos 
disease. Also, markers should assist in the decision making 
of the therapy process, that is, selecting patients for a specific 
therapeutic approach.
Measurement of the serum concentrations of soluble 
mesothelin-related protein (SMRP or mesothelin) has been 
proposed by various groups as a valuable tool for the diagnosis 
of MPM.3–5 However, differentiation among patients with 
MPM, benign asbestos disease, and LC was found to be rather 
poor with respect to specificity and sensitivity.6 It has been 
known for a long time that carcinoembryonic antigen (CEA) 
is down-regulated in MPM7,8 but is elevated in various other 
lung conditions, that is, LC.9 The aim of this retrospective 
study was to improve our previously published results6 of the 
mesothelin test with regard to diagnostic accuracy and the 
power to differentiate between patients with MPM, primary 
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LC, and benign lung disease related to asbestos exposure, 
by combining these results with the results of an additional 
CEA measurement. In this respect, we applied a quotient of 
mesothelin and CEA serum levels.
PATIENTS AND METHODS
Patients
In this retrospective study, 93 patients (87 men, 6 women; 
aged 62 ± 8.3 years) with cytologically or histologically con-
firmed but previously untreated MPM were examined. On the 
basis of World Health Organization criteria,10 the histological 
subtyping of the untreated patients yielded 66 epithelial, 15 
biphasic, and 12 sarcomatoid MPMs. According to the Union 
for International Cancer Control (UICC) recommendations11 
there were six stage I, 20 stage II, 36 stage III, and 31 stage IV 
MPMs. The group of 139 patients with newly diagnosed pri-
mary LC (122 men, 16 women; mean age, 65 ± 9.6 years) con-
sisted of 25 small-cell carcinomas (65 ± 9.2 years), three large 
cell carcinomas (67 ± 4.4 years), 61 squamous cell carcinomas 
(66 ± 8.1 years), and 50 ACs (62 ± 11.6 years). The exclusion 
criteria were any cancer-specific therapy before venepuncture, 
pulmonary metastases of extrapulmonary tumors, sarcoma, 
and lymphoma. The tumor patients were compared with a 
control group of 75 patients (74 men, 1 woman) with benign 
asbestos-related disease (for criteria for diagnosis, see refs. 
12,13) that is, 19 patients with pleural plaques (65 ± 4.9 years), 
49 patients with hyalinosis complicata or rounded atelectasis 
(64 ± 8.1 years) (for diagnosis, see ref. 14), and seven patients 
with lung asbestosis (small irregular opacities at a profusion of 
greater than or equal to one of one, according to International 
Labor Organisation criteria) (60 ± 6.6 years).15 The serum sam-
ples were collected between 1998 and 2005.
Written consent was obtained from all participants for 
the use of their blood samples for biomarker testing. The study 
was approved by the local clinical review boards.
Methods
Blood serum samples were processed within 120 min-
utes after venepuncture. Sera were kept frozen at −80°C, 
until analysis.
SMRP (mesothelin) was quantified by the sandwich-
type ELISA kit MesoMark (Fuji Rebio Diagnostic, Malvern, 
PA; distributed by CIS bio GmbH, Germany). CEA was mea-
sured with Advia Centaur immunoassay (Siemens Healthcare 
Diagnostics Inc., Tarrytown, NY). Both tests were performed 
according to the manufacturers’ instructions.
Statistical Analysis
Data were statistically analyzed with SPSS 18.0 for 
Windows (SPSS, Chicago, IL). Because the distribution 
found in all groups was not normal, the statistical compari-
sons among the groups were carried out by the nonparamet-
ric Mann–Whitney U test. A p value less than 0.05, resulting 
from a two-sided test, was considered as statistically sig-
nificant. Results of mesothelin measurement in the various 
subsets of patients were expressed as median and range. In 
addition, box-plots were created. The box represented the 
25% to 75% quartiles. The whiskers indicated the ± 1.5-fold 
interquartile range up to the last value included. Values out-
side the 1.5-fold interquartile range were signed as extreme 
values. The medians were given as horizontal lines. Receiver 
operating characteristics (ROC) curves were used to analyze 
test accuracy. Optimal cutoff values, which define the best 
diagnostic efficiency, were calculated according to Youden 
index (Y
i
 = sensitivity + specificity − 1).16 The cutoff value 
that resulted in a maximum value of Y
i
 was considered as the 
optimal cutoff value.
RESULTS
Table 1 summarizes the results of mesothelin and CEA 
concentration measurements in the various study groups. 
Mesothelin was found to be significantly increased in patients 
suffering from MPM in comparison with those with benign 
asbestos disease (p < 0.0001), or primary LC (p < 0.0001). 
The median values were found to be 1.4 nmol/L, 0.9 nmol/L, 
and 0.8 nmol/L, respectively. There was no significant dif-
ference between mesothelin concentrations in benign asbes-
tos disease and LC (p = 0.7). The highest CEA levels were 
found in LC followed by benign asbestos disease and MPM. 
The mesothelin/CEA ratio was significantly different among 
MPM, LC, and benign asbestos disease (p < 0.0001 for each 
groupwise comparison).
In Figure 1, the mesothelin concentration is plotted 
against the CEA concentration in the various study groups. 
MPM and LC patients can be separated clearly by the use of 
both markers.
In Figure 2 the data distribution of CEA, mesothelin, 
and the quotient mesothelin/CEA are given as a box plot. 
There was much less overlap between boxes of the MPM and 
LC group for the mesothelin/CEA quotient compared with 
mesothelin alone or CEA.
The differing diagnostic accuracies among MPM, 
LC, and benign asbestos disease are shown as ROC curves 
in Figure 3. For the comparison of MPM and LC, the quo-
tient mesothelin/CEA resulted in a nearly perfect ROC 
curve. The AUC was found to be 0.987. In contrast, meso-
thelin alone gave an AUC of only 0.708, and CEA resulted 
in an AUC of 0.011. The differentiation between MPM and 
benign asbestos disease was, similarly, improved by the use 













MPM 93 1.4 (0.2–31.0) 0.3 (0.1–3.0) 6.0 (0.4–310.0)




75 0.9 (0.1–3.3) 1.4 (0.1–9.8) 0.66 (0.01–6.5)
CEA, carcinoembryonic antigen; LC, lung cancer.
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AUC of 0.715 for mesothelin alone and an AUC of 0.16 for 
CEA alone.
Table 2 summarizes the results of sensitivity and speci-
ficity rates for various comparisons. The sensitivity rate was 
93% (69%) at 95% (100%) specificity for the differentiation 
between MPM and LC, and 56% (47%) at 95% (100%) spec-
ificity between MPM and benign asbestos disease patients. 
By using the quotient mesothelin/CEA, an average incre-
ment in sensitivity of 38% (range, 16%–63%) compared with 
mesothelin alone could be achieved. Similarly, after Youdon 
optimization the improvement of sensitivity with an incre-
ment of at least 34% for the marker combination mesothelin/
CEA remains.
DISCUSSION
Our current data clearly show that a combination of 
mesothelin and CEA as a quotient significantly facilitates the 
differential diagnosis between mesothelioma, LC, and benign 
asbestos disease. In our recent article,6 the differentiating 
power was found to be suboptimal, using mesothelin alone. 
This is because of the fact that there is a considerable overlap 
between serum mesothelin levels in mesothelioma, LC, and 
benign asbestos disease, impeding the differential diagnosis. 
The resulting sensitivity and specificity rates with a calculated 
AUC of approximately 0.708 are not sufficient to differentiate 
between either MPM and LC, or between MPM and benign 
asbestos disease. This is in accordance with the findings of 
Scherpereel et al.,4 where the AUC values of the ROC curves 
for mesothelin were found to be significantly higher in patients 
with MPM compared with controls with benign disease 
(AUC = 0.872), whereas differentiation of MPM from other 
malignant diseases was significantly lower (AUC = 0.693). 
Besides this finding, the poor sensitivity of mesothelin clearly 
limits its added value to early diagnosis and emphasizes the 
need for further biomarker research.18
CEA is a negative predictor for MPM and CEA expres-
sion and seems to be down-regulated in MPM when com-
pared with LC or benign asbestos disease.8,19 However, a low 
level of CEA (median, 0.3 ng/mL) alone can neither prove, 
nor exclude MPM. Usually, low CEA levels suggest benign 
disease. In contrast, LC patients are known to have increased 
CEA serum levels.9
Therefore, we decided to combine the two markers 
mesothelin and CEA in a quotient. In MPM we expected an 
increased quotient (mesothelin/CEA) because of the positive- 
correlated marker mesothelin with the negative- correlated 
marker CEA. In contrast we expected a decreased quotient 
for LC. As a result, the quotient mesothelin/CEA significantly 
improved the differentiation between MPM and LC, as well as 
between MPM and benign asbestos disease. At 95% specificity, 
an increase in sensitivity between 14% (versus benign asbes-
tos disease) up to 63% (versus LC) could be achieved. For the 
comparison of MPM and LC the AUC was found to be 0.987.
These results are in good accordance with the AUC of 
0.94 described for MPM and non–small-cell cancer by van 
den Heuvel et al.19 In addition, the differentiation between 
MPM and benign asbestos disease was likewise improved by 
the use of the quotient, with an AUC of 0.887 compared with 
an AUC of 0.715 for mesothelin alone.
In a systematic review, the frequently investigated serum 
markers SMRP (mesothelin), CEA, Ber-EP4 (antihuman epi-
thelial antigen), and calretinin were most valuable in discrimi-
nating mesothelioma from other malignant diseases.20 The 
markers epithelial membrane antigen and mesothelin were 
most valuable in differentiating mesothelioma from nonma-
lignant diseases. However, no marker performed sufficiently 
well in discriminating mesothelioma from all other diseases. 
Therefore, the use of single-tumor markers remains of limited 
diagnostic value.
Various marker combinations and complex algorithms 
have been suggested for differential diagnosis between 
benign and malignant thoracic diseases. For example, a 
fuzzy-classifier using a marker panel of cytokeratin fragment 
21-1 (CYFRA 21-1), neuron specific enolase (NSE), and 
C-reactive protein (CRP) significantly improved detection of 
LCs in asbestosis patients.21 A similar approach might prob-
ably be useful for MPM diagnosis.
Van den Heuvel et al.19 evaluated a combination of 
mesothelin, CEA, and CYFRA 21-1. Although CYFRA 
21-1 was able to discriminate between normal and malignant 
disease, only the two serum markers, CEA and mesothelin, 
proved capable of discriminating MPM from non–small-cell 
lung cancer, with a sensitivity of 66% at 96% specificity. A 
sensitivity rate of 93% (69%) at 95% (100%) specificity was 
found for the differentiation between MPM and LC, and may 
therefore, be a useful diagnostic tool to distinguish between 
both malignancies more accurately.
In a different study, a combination of mesothelin 
with osteopontin was analyzed in MPM compared with 
healthy persons and patients with benign lung diseases.22 
An increased sensitivity and specificity was reported for 
the combination. However, no data in relation to differen-
tial diagnosis to LC were presented. In our view, this seems 
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measurement of osteopontin suffers for some technical and 
analytical problems, on which we had commented in our 
recent article.6
In pleural effusions, Blanquart et al.17 recently intro-
duced a combination of chemokine chemokine (C-C motif) 
ligand 2 (CCL2), Galectin-3, and SMRP as a favorable tool to 
differentiate MPM from AC and benign pleural effusions. The 
AUC of the ROC curve of their logistic regression model was 
found to be 0.968 and close to the AUC reported by us. The 
usefulness of their model in serum samples, which might offer 
a diagnostic solution for a broader patient group, remains to 
be demonstrated.
Ostroff et al.23 reported on a biomarker discovery assay 
by measurement of more than 1000 proteins simultaneously 
in biological samples, applying a DNA aptamer-technology. 
After multivariate approaches 64 candidate protein biomarkers 
were identified and a 13-protein classifier was validated. The 
classifier accuracy for detection of MPM in the asbestos-
exposed population was maintained in a blinded validation set, 
with a sensitivity of 90%, a specificity of 89%, and an overall 
accuracy of 92%. The proteins were related to inflammation 
and regulation of cellular proliferation.To date, none of the 
classifier biomarkers have previously been associated with 
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this group, but other markers proved to be superior. In paired 
samples, the random forest classifier AUC of 0.99 and 91%/94% 
sensitivity/specificity was superior to that of mesothelin with an 
AUC of 0.82 and 66%/88% sensitivity/specificity. Differential 
expression of CEA was not statistically significant.
Our data of the marker combination mesothelin/CEA 
in the detection and differentiation of patients with MPM 
and primary LC in comparison with benign diseases related 
to asbestos exposure resulted in a comparable outcome. 
Mesothelin and CEA are relatively easy to measure. Complex 
mathematical procedures are not required. On the basis of the 
data reported here, the use of both tests can, therefore, be rec-
ommended for diagnosis and differential diagnosis.
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Non-MPMa 2.37 (6.75) 95% (100%) 67% (47%) 32%b
Benign asbestos disease 4.23 (6.75) 95% (100%) 56% (47%) 40%b
LC 0.9 (2.32) 95% (100%) 93% (69%) 30%b
Optimized cutoff (Youdenb)
Non-MPMa 1.18 88% 89% 55%b
Benign asbestos disease 1.18 72% 89% 51%b
LC 0.83 94% 96% 55%b
Sensitivity rates for mesothelin alone at 95% and after Youden optimization are shown in the right row.
aNon-MPM= benign asbestos disease +LC.
bCutoff values differ from those of mesothelin/CEA.
CEA, carcinoembryonic antigen; LC, lung cancer; MPM, malignant pleural mesothelioma.
